Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher – Should You Buy?

Turn Therapeutics Inc. (NASDAQ:TTRX)’s share price traded up 6% during trading on Friday . The stock traded as high as $3.55 and last traded at $3.55. 15,975 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 29,635 shares. The stock had previously closed at $3.35.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TTRX. Weiss Ratings began coverage on Turn Therapeutics in a research report on Monday, January 5th. They set a “sell (e-)” rating for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a report on Tuesday, March 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Turn Therapeutics has an average rating of “Hold” and an average target price of $8.00.

Turn Therapeutics Trading Up 6.0%

The firm has a market capitalization of $105.75 million and a P/E ratio of -22.19. The business’s 50 day simple moving average is $3.44.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.09) earnings per share for the quarter.

Institutional Investors Weigh In On Turn Therapeutics

A number of large investors have recently added to or reduced their stakes in TTRX. Hodges Capital Management Inc. bought a new position in Turn Therapeutics during the 4th quarter worth approximately $39,000. LPL Financial LLC purchased a new position in Turn Therapeutics during the 4th quarter valued at $51,000. Tamar Securities LLC bought a new position in Turn Therapeutics in the fourth quarter worth about $59,000. Composition Wealth LLC purchased a new position in shares of Turn Therapeutics during the 4th quarter worth approximately $63,000. Finally, Jane Street Group LLC purchased a new position in shares of Turn Therapeutics during the 4th quarter worth approximately $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.